The Nasdaq Stock Market LLC's listing qualifications department notified Bio-Path Holdings Inc. that it has regained compliance with the exchange's minimum bid price requirement.

The closing bid price of Bio-Path common stock has been at $1.00 per share or more from Feb. 9 through Feb. 23.

The Texas-based cancer drugmaker received the noncompliance notice in September 2017.